Search

Author/Creator Kim, Tae Min

1. 288 A phase 1 study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. (9th November 2020)

Authors:
Keam, Bhumsuk; Kim, Tae Min; Oh, Do-Youn; Ock, Chan-Young; Kang, Won Ki; Park, Yeon Hee; Lee, Jeeyun; Lee, Ji Hye; Song, Yun Jeong; Park, Young Suk
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A315
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016)

Authors:
Ager, Casey; Reilley, Matthew; Nicholas, Courtney; Bartkowiak, Todd; Jaiswal, Ashvin; Curran, Michael; Albershardt, Tina C.; Bajaj, Anshika; Archer, Jacob F.; Reeves, Rebecca S.; Ngo, Lisa Y.; Berglund, Peter; ter Meulen, Jan; Denis, Caroline; Ghadially, Hormas; Arnoux, Thomas; Chanuc, Fabien; Fu...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 4(2016)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A Phase II Study of Ifosfamide, Methotrexate, Etoposide, and Prednisolone for Previously Untreated Stage I/II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Multicenter Trial of the Korean Cancer Study Group. (3rd October 2014)

Authors:
Kim, Tae Min; Kim, Dong-Wan; Kang, Yoon-Koo; Chung, Jooseop; Song, Hong-Suk; Kim, Hyo Jung; Kim, Byung Soo; Lee, Jong-Seok; Kim, Hawk; Yang, Sung Hyun; Yuh, Young Jin; Bae, Sung Hwa; Hyun, Myung Soo; Jeon, Yoon Kyung; Kim, Chul Woo; Heo, Dae Seog
Journal:
Oncologist
Issue:
Volume 19:Number 11(2014)
Page Start:
1129
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A Phase II Study of Ifosfamide, Methotrexate, Etoposide, and Prednisolone for Previously Untreated Stage I/II Extranodal Natural Killer/T‐Cell Lymphoma, Nasal Type: A Multicenter Trial of the Korean Cancer Study Group. (3rd October 2014)

Authors:
Kim, Tae Min; Kim, Dong‐Wan; Kang, Yoon‐Koo; Chung, Jooseop; Song, Hong‐Suk; Kim, Hyo Jung; Kim, Byung Soo; Lee, Jong‐Seok; Kim, Hawk; Yang, Sung Hyun; Yuh, Young Jin; Bae, Sung Hwa; Hyun, Myung Soo; Jeon, Yoon Kyung; Kim, Chul Woo; Heo, Dae Seog
Journal:
Oncologist
Issue:
Volume 19:Number 11(2014)
Page Start:
1129
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. (24th August 2015)

Authors:
Lee, Keun-Wook; Koh, Youngil; Kim, Sung-Bae; Shin, Sang-Won; Kang, Jin-Hyoung; Wu, Hong-Gyun; Sung, Myung-Whun; Keam, Bhumsuk; Kim, Dong-Wan; Kim, Tae Min; Kim, Kwang Hyun; Kwon, Tack-Kyun; Hah, J. Hun; Kim, In-Ah; Ahn, Soon-Hyun; Yoon, Dok Hyun; Lee, Sang-Wook; Kim, Sang Yoon; Nam, Soon Yuhl; Ju...
Journal:
Oncologist
Issue:
Volume 20:Number 10(2015)
Page Start:
1119
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. (24th August 2015)

Authors:
Lee, Keun‐Wook; Koh, Youngil; Kim, Sung‐Bae; Shin, Sang‐Won; Kang, Jin‐Hyoung; Wu, Hong‐Gyun; Sung, Myung‐Whun; Keam, Bhumsuk; Kim, Dong‐Wan; Kim, Tae Min; Kim, Kwang Hyun; Kwon, Tack‐Kyun; Hah, J. Hun; Kim, In‐Ah; Ahn, Soon‐Hyun; Yoon, Dok Hyun; Lee, Sang‐Wook; Kim, Sang Yoon; Nam, Soon Yuhl; Ju...
Journal:
Oncologist
Issue:
Volume 20:Number 10(2015)
Page Start:
1119
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Issue 11 (November 2017)

Authors:
Ahn, Myung-Ju; Kim, Dong-Wan; Cho, Byoung Chul; Kim, Sang-We; Lee, Jong Seok; Ahn, Jin-Seok; Kim, Tae Min; Lin, Chia-Chi; Kim, Hye Ryun; John, Thomas; Kao, Steven; Goldman, Jonathan W; Su, Wu-Chou; Natale, Ronald; Rabbie, Sarit; Harrop, Bryony; Overend, Philip; Yang, Zhenfan; Yang, James Chih-Hsin
Journal:
Lancet
Issue:
Volume 5:Issue 11(2017)
Page Start:
891
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. An increase in indoleamine 2, 3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. Issue 8 (2nd August 2016)

Authors:
Nam, Soo Jeong; Kim, Sehui; Paik, Jin Ho; Kim, Tae Min; Heo, Dae Seog; Kim, Chul Woo; Jeon, Yoon Kyung
Journal:
Leukemia & lymphoma
Issue:
Volume 57:Issue 8(2016:Aug.)
Page Start:
1956
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Issue 11 (November 2014)

Authors:
Nam, Soo Jeong; Go, Heounjeong; Paik, Jin Ho; Kim, Tae Min; Heo, Dae Seog; Kim, Chul Woo; Jeon, Yoon Kyung
Journal:
Leukemia & lymphoma
Issue:
Volume 55:Issue 11(2014:Nov.)
Page Start:
2466
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗